HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tremlett, H. L. Articles by Oger, J. Search for Related Content PubMed PubMed Citation Articles by Tremlett, H. L. Articles by Oger, J. Related Collections All Clinical trials Clinical trials Observational study (Cohort, Case control) Multiple sclerosis

Interrupted therapy

Stopping and switching of the ß-interferons prescribed for MS

From the Division of Neurology, Department of Medicine, University of British Columbia, Vancouver Hospital and Health Sciences Center, Canada.

Address correspondence and reprint requests to Dr. H.L. Tremlett, Division of Neurology, Department of Medicine, Vancouver Hospital and Health Sciences Center, UBC Site, S159-2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5; e-mail: tremlett{at}interchange.ubc.ca

A retrospective chart review of patients in British Columbia with multiple sclerosis prescribed ß-interferon (IFNß) between 1995 and 2001 was carried out to investigate reasons for the interruption of therapy. The highest proportion of interruptions (76/281; 27%) occurred in the first 6 months. The single most common reason was perceived lack of efficacy, cited by 84 of 281 (30%). Gender, disability, and disease duration were identified as factors influencing interruption of IFNß therapy.

This article has been cited by other articles:

				A Gajofatto, P Bacchetti, B Grimes, A High, and E Waubant Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis Multiple Sclerosis, January 1, 2009; 15(1): 50 - 58. [Abstract] [PDF]

				S Minden, D Hoaglin, S Jureidini, L Hadden, D Frankel, Y Komatsuzaki, and J Outley Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study Multiple Sclerosis, June 1, 2008; 14(5): 640 - 655. [Abstract] [PDF]

				L.I. Iezzoni, L.H. Ngo, and R.P. Kinkel Working-age persons with multiple sclerosis and access to disease-modifying medications Multiple Sclerosis, January 1, 2008; 14(1): 112 - 122. [Abstract] [PDF]

				C. Boz, J. Oger, E. Gibbs, S.E. Grossberg, and the Neurologists of the UBC MS Clinic Reduced effectiveness of long-term interferon-{beta} treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study Multiple Sclerosis, November 1, 2007; 13(9): 1127 - 1137. [Abstract] [PDF]

				A.P. Turner, D.R. Kivlahan, A.P. Sloan, and J.K. Haselkorn Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model Multiple Sclerosis, November 1, 2007; 13(9): 1146 - 1152. [Abstract] [PDF]

				J. Rio, J. Porcel, N. Tellez, A. Sanchez-Betancourt, M a. Tintore, M J. Arevalo, C. Nos, and X. Montalban Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis Multiple Sclerosis, June 1, 2005; 11(3): 306 - 309. [Abstract] [PDF]

				K E. O'Rourke and M Hutchinson Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns Multiple Sclerosis, February 1, 2005; 11(1): 46 - 50. [Abstract] [PDF]